Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Advanced Prostate Cancer Drug Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HOXB13 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HOXB13 Wild-Type & G84E Mutant Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for PPI screening. |
View HOXB13 Products |
| Gene Delivery | HOXB13 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and nuclear localization assays. |
View HOXB13 Products |
| Benchmark Ab | Anti-HOXB13 Recombinant Antibody Recombinant positive control for western blot, ChIP, and IHC validation. |
View HOXB13 Products |
| Validator | HOXB13 siRNA Set For target knockdown verification and functional rescue assays. |
View HOXB13 Products |
| Related Target A | Androgen Receptor (AR) Key synergistic transcription factor in prostate cancer progression and resistance pathways. |
View AR Products |
| Related Target B | FOXA1 Pioneer factor that co-localizes with HOXB13 to drive oncogenic chromatin remodeling. |
View FOXA1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Targeting Intracellular Transcription Factors | Lentivirus premade particles for robust cellular expression and reporter assays |
| G84E Hereditary Mutation Screening | Sequence-verified G84E mutant recombinant proteins with >95% purity |
| Lack of Controls | Sequence-defined recombinant benchmark antibodies included |
| False Positives in PPI Assays | Validated siRNA sets included for functional knockdown specificity checks |
Live HOXB13 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for HOXB13 therapeutics is intensifying, with major players shifting focus from traditional hormone therapies to targeting undruggable transcription factors. As first-generation androgen receptor (AR) inhibitors face resistance in castration-resistant prostate cancer (CRPC), the next wave of R&D is targeting HOXB13-mediated transcription networks and its critical co-factors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Molecular Glue | Arvinas, Accutar Biotechnology | mCRPC, AR-V7+ Prostate Cancer | Target Degradation Assay (Need high-purity WT/Mutant proteins for ternary complex biophysics) |
| Small Molecule PPI Inhibitor | Prestige Biopharma, Academic Spin-offs | Hereditary Prostate Cancer (G84E) | Protein-Protein Interaction Assay (Need HOXB13-MEIS1 or HOXB13-DNA binding validation) |
| RNA Therapeutics (siRNA/ASO) | Alnylam, Ionis Pharmaceuticals | Advanced Solid Tumors | Knockdown Efficiency Validation (Need validated siRNA sets and Lentivirus controls) |